Merck | MRK - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Abbott USD 2.13B 281M 2026-06
ALKERMES USD -65.93M 17.65M 2026-06
Amgen USD 4.61B 777M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Biogen USD -243.8M 758.1M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Coherus Biosciences USD -39.08M 3.65M 2025-12
Drreddys Laboratories INR 829M 13.5B 2026-03
Eli Lilly USD 12.46B 2.68B 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Glaxosmithkline GBP 2.29B 3.08M 2026-03
J&J USD 7.48B 860M 2026-06
Medtronic USD 2.09B 354M 2026-03
Merck USD 840M 2.72B 2026-06
Novartis USD 4.75B 515M 2026-06
Novartis USD 4.24B 171M 2026-03
Novo Nordisk DKK 33.76B 25.86B 2026-06
Pacira USD 9.96M 5.33M 2026-06
Perrigo USD 23.5M 10.1M 2026-06
Pfizer USD 667M 4.32B 2026-06
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 52.52M 22.97M 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 2.38B 449M 2026-06
Sanofi EUR 2.27B 771M 2026-03
United Therapeutics USD 330.8M 5M 2026-06
Zoetis USD 1.12B 256M 2026-06